Gilead Sciences pauses enrollment globally in magrolimab solid tumor studies

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-02-17 09:13 GMT | Update On 2024-03-21 11:04 GMT

Foster City: Gilead Sciences, Inc. has announced that it has paused enrollment globally in the magrolimab solid tumor studies. The U.S. Food and Drug Administration (FDA) subsequently requested a partial clinical hold on these trials. This request is in addition to the previously announced full clinical hold on all magrolimab studies in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) requested by the FDA.

"Gilead is reviewing the benefit-risk of magrolimab across all ongoing trials and will provide an update on this assessment as soon as possible.

Patients already enrolled in the Gilead-sponsored ELEVATE solid tumor studies and deriving clinical benefit may continue to choose receiving magrolimab following reconsenting to the study with their healthcare provider," the Company stated in a recent release.

The Gilead-sponsored ELEVATE solid tumor studies impacted by the partial clinical hold include:

Phase 2 study in head and neck squamous cell carcinoma (NCT04854499)
Phase 2 study in solid tumors (NCT04827576)
Phase 2 study in triple-negative breast cancer (NCT04958785)
Phase 2 study in colorectal cancer (NCT05330429)

The enrollment hold also applies to Investigator Sponsored Studies with magrolimab in solid tumors.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Gilead Sciences pauses enrollment globally in magrolimab solid tumor studies

Similar News

CDSCO Flags 112 Drug Batches Including Telmisartan, Pantoprazole, Cefixime, Glimepiride as Not of Standard Quality

Zydus bags Health Canada approval for Mesalamine suppositories for active ulcerative proctitis

Bayer Lynkuet gets USFDA nod for treatment of moderate to severe vasomotor symptoms due to menopause

Telangana: Medical shop seized, licence cancelled for illegal sale of Schedule H1 drugs

Aurobindo Pharma arm Eugia Pharma B.V incorporates wholly owned subsidiary in Chile

Lupin unveils authorized generic version of Ravicti in US

Manipur: 91 bottles of psychotropic cough syrup seized, 1 arrested

GSK Blenrep approved by USFDA for relapsed/refractory multiple myeloma